| scholarly article | Q13442814 |
| P2093 | author name string | Shampur Narayan Madhusudana | |
| Belludi Yajaman Ashwin | |||
| Sampada Sudarshan | |||
| P2860 | cites work | First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity | Q33370751 |
| Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans | Q33514828 | ||
| Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons | Q36880828 | ||
| Effects of homologous or heterologous antiserum on neutralizing-antibody response to rabies vaccine. | Q36911052 | ||
| Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines | Q39374912 | ||
| Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults | Q39547355 | ||
| Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey | Q39754170 | ||
| EXCRETION OF STREET RABIES VIRUS IN THE SALIVA OF DOGS. | Q45255860 | ||
| Excretion of rabies virus in the saliva of dogs | Q45792925 | ||
| Equine rabies immune globulin: a product with an undeserved poor reputation. | Q45978767 | ||
| Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis | Q46317797 | ||
| Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. | Q51901413 | ||
| Additional reports of failure to respond to treatment after rabies exposure in Thailand | Q74460219 | ||
| Use of hyperimmune anti-rabies serum concentrates in experimental rabies | Q80667155 | ||
| WHO Expert Consultation on rabies | Q82586229 | ||
| P433 | issue | 9 | |
| P921 | main subject | rabies | Q39222 |
| immunization | Q1415366 | ||
| rabies immunoglobulin | Q4067112 | ||
| passive immunization | Q73525231 | ||
| P304 | page(s) | 1914-1917 | |
| P577 | publication date | 2013-06-21 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: results of In vitro and In vivo studies | |
| P478 | volume | 9 |
| Q56576872 | Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin |
| Q47571006 | Immunogenic response in obese patients undergoing rabies post-exposure prophylaxis with combined equine rabies immunoglobulin and rabies vaccination |
| Q40300404 | Injecting rabies immunoglobulin (RIG) into wounds only: A significant saving of lives and costly RIG. |
| Q37135159 | Local infiltration of rabies immunoglobulins without systemic intramuscular administration: An alternative cost effective approach for passive immunization against rabies |
| Q37664750 | Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies |
| Q40340145 | Role of systemic injection of rabies immunoglobulin in rabies vaccination |
| Q90252514 | Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial |
Search more.